Clinical Trials Involving Treatment Resistant Depression

Author : Andrea Sony | Published On : 11 Jan 2022

Data from a study in adults with treatment-resistant depression showed that flexibly-dosed esketamine nasal spray plus a newly initiated oral antidepressant demonstrated a statistically significant, clinically meaningful reduction of depressive symptoms compared with placebo.Johnson & Johnson subsidiary Janssen has presented its Phase 3 data for its esketamine nasal spray for treatment-resistant depression for the first time in Europe at the International College of Neuropsychopharmacology in Vienna, Austria.